课题基金 / 基金详情

EHR-based Genomic Discovery and Implementation

EHR-based Genomic Discovery and Implementation
基于 EHR 的基因组发现和实施
批准号:
10207706
负责人:
Iftikhar J Kullo
金额:
$127.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
未结题
起止时间:
2011-08-15 至 2025-04-30

项目摘要

项目成果

Iftikhar J Kullo的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 在本应用程序中,我们建议在Emerge的前三个阶段工作的基础上开发和 验证15种常见疾病的多基因风险评分(PR),并将其与临床风险评分和 家族史,为2500人(35%非欧洲血统)创建全面的风险档案。我们会 开发表型算法以识别这15种疾病的病例和对照,并确定临床风险 通过从电子健康记录(EHR)中提取相关变量,对每种疾病进行评分。接下来,使用 现有Emerge基因型和表型数据(n=105,000)和公开可用的(TopMed,AoU,MVP, UKBB)数据集,我们将使用新方法计算候选基因座或基因组范围的PR,以使其适应 特定的种族/民族群体。经过验证的PRS将与家族病史和临床风险评分相结合,以 创建全面的风险配置文件。我们之前曾将这种方法应用于冠心病, 我们已经做好了充分的准备,可以将其扩展到另外14种常见疾病。要评估可持续发展在 未来队列,我们将从罗切斯特明尼苏达州招募参与者(1800名成年人和200名青少年)和 凤凰城亚利桑那州(500名西班牙裔成年人)。DNA将被送往CLIA认证的基因组测试,我们将 计算种族/民族特定的PR。将向参与者和提供者报告个性化的风险评估 并放在EHR中,链接到临床决策支持(CDS),包括基于指南的风险- 管理信息。对于风险显著较高的参与者,他们患上至少1 15种疾病(估计占队列的25%),结果将亲自披露,然后评估 结果包括订购的新测试、降低风险的措施和可更改的风险因素的变化。在……里面 此外,我们还将研究返回原籍的经济、行为和心理社会影响。我们的重点是 On Prs将基因组药物带给人们,我们将继续与Mountain Park建立合作伙伴关系 Health Center是一家FQHC,服务于凤凰城亚利桑那州的低收入少数族裔社区,以解决人们的担忧 关于基因组医学背景下的健康差异。我们的具体目标包括:1)利用现有资源 105,000名Emerge参与者的基因和EHR数据以及其他公开可用的数据集 验证15种常见疾病的Prs;2)部署新的方法,将Prs集成到EHR中,并与 CDS结合了基于指南的临床建议,并开发了可扩展的披露方法 将结果提供给参与者;3)招募2500人进行CLIA基因分型,使用密集SNP阵列和 返回包括PR在内的全面风险简档;4)评估临床、成本/利用率和社会心理 返回结果后的结果。
英文摘要
PROJECT SUMMARY In this application we propose to build on our work in the previous three phases of eMERGE to develop and validate polygenic risk scores (PRS) for 15 common diseases and combine these with clinical risk scores and family history to create comprehensive risk profiles for 2500 individuals (35% non-European ancestry). We will develop phenotyping algorithms to identify cases and controls for the 15 diseases and ascertain clinical risk scores for each disease by extracting relevant variables from the electronic health record (EHR). Next, using existing eMERGE genotype and phenotype data (n=105,000) and publicly available (TopMed, AoU, MVP, UKBB) datasets, we will calculate candidate loci or genome wide PRS using novel methods to adapt these to specific racial/ethnic groups. Validated PRS will be combined with family history and clinical risk scores to create comprehensive risk profiles. We have previously applied such methodology for coronary heart disease, positioning us well to expand this to 14 additional common diseases. To assess the utility of PRS in a prospective cohort, we will recruit participants from Rochester MN (1800 adults and 200 adolescents) and Phoenix AZ (500 adults of Hispanic ethnicity). DNA will be sent for CLIA-certified genomic testing and we will calculate race/ethnicity specific PRS. Individualized risk estimates will be reported to participants and providers and placed in the EHR with linkage to clinical decision support (CDS) that includes guideline-based risk- management information. For participants who are at significantly higher risk for developing at least 1 of the 15 diseases (estimated 25% of the cohort), results will be disclosed in-person followed by assessment of outcomes including new tests ordered, risk reduction measures, and changes in modifiable risk factors. In addition we will examine the economic, behavioral and psychosocial implications of returning PRS. Our focus on PRS brings genomic medicine to the population and we will continue our partnership with Mountain Park Health Center, a FQHC serving low-income, minority communities across Phoenix AZ, to address concerns about health disparities in the context of genomic medicine. Our specific aims include: 1) Utilize extant genotype and EHR data on 105,000 eMERGE participants as well as other publicly available datasets to validate PRS for 15 common diseases; 2) Deploy novel methods for integrating PRS in the EHR with linkage to CDS that incorporates guideline based clinical recommendations and develop scalable methods for disclosing PRS results to participants; 3) Enroll 2500 persons to undergo CLIA genotyping using dense SNP arrays and return comprehensive risk profiles that include PRS; 4) Assess clinical, cost/utilization and psychosocial outcomes following return of results.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Polygenic Risk of Disease in Populations of Diverse Ancestry
  • 批准号:
    10210804
  • 项目类别:
  • 资助金额:
    $68.54万
  • 财政年份:
    2021
  • 负责人:
    Iftikhar J Kullo
  • 依托单位:
Polygenic Risk of Disease in Populations of Diverse Ancestry
  • 批准号:
    10670372
  • 项目类别:
  • 资助金额:
    $60.41万
  • 财政年份:
    2021
  • 负责人:
    Iftikhar J Kullo
  • 依托单位:
EHR-Based Strategies to Improve Outcomes in Familial Hypercholesterolemia
  • 批准号:
    9389934
  • 项目类别:
  • 资助金额:
    $52.01万
  • 财政年份:
    2017
  • 负责人:
    Iftikhar J Kullo
  • 依托单位:
Patient-Oriented Research in Genomic Discovery and Implementation
  • 批准号:
    10221769
  • 项目类别:
  • 资助金额:
    $11.81万
  • 财政年份:
    2017
  • 负责人:
    Iftikhar J Kullo
  • 依托单位:
海外基金